Evidence map›Paper›PMID 20379614›Full record

Trial reportMolecular medicine (Cambridge, Mass.)

Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score.

Jed E Rose, Frédérique M Behm, Tomas Drgon, Catherine Johnson, George R Uhl

Erratum issuedAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Molecular medicine (Cambridge, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 83 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Smoking reduction interventions for smoking cessation.The Cochrane database of systematic reviews · 2019
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

5 authors.

Jed E RoseDepartment of Psychiatry and Center for Nicotine and Smoking Cessation Research, Duke University, Durham, North Carolina 27705, USA. rose0003@mc.duke.edu
Frédérique M Behm
Tomas Drgon
Catherine Johnson
George R Uhl

Funding

Recruitment CoreP50DA027840 · NIDA · DUKE UNIVERSITY · PI DAVIS, JAMES M · 2010 to 2019
$14.9M
Molecular Genetic Bases for Quit SuccessZIADA000537 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI UHL, GEORGE RICHARD · 2009 to 2015
$2.9M
Intramural NIH HHSNIDA NIH HHS P50 DA027840
6 · The paper itself

Abstract

Improving and targeting nicotine replacement therapy (NRT) are cost-effective strategies for reducing adverse health consequences for smokers. Treatment studies document the efficacy of precessation NRT and support important roles for level of nicotine dependence and precessation smoking reduction in successful quitting. However, prior work has not identified the optimal precessation dose or means for personalizing NRT. Genome-wide association has identified groups of genomic markers associated with successful quitting, allowing us to develop a v1.0 "quit-success" genotype score. We now report influences of v1.0 quit-success genotype score, level of dependence and precessation smoking reduction in a smoking cessation trial that examined effects of 21 versus 42 mg/24 h precessation NRT. Four hundred seventy-nine smokers were randomized to 21 or 42 mg NRT, initiated 2 wks prior to target quit dates. We monitored self-reported abstinence and end-expired air carbon monoxide (CO). Genotyping used Affymetrix arrays (Santa Clara, CA, USA). The primary outcome was 10-wk continuous smoking abstinence. NRT dose, level of nicotine dependence and genotype scores displayed significant interactive effects on successful quitting. Successful abstinence also was predicted by CO reductions during precessation NRT. These results document ways in which smoking cessation strategies can be personalized based on levels of nicotine dependence, genotype scores and CO monitoring. These assessments, taken together, can help match most smokers with optimal NRT doses and help rapidly identify some who may be better treated using other methods.

Indexed as

Administration, CutaneousAdultCarbon MonoxideDelayed-Action PreparationsDouble-Blind MethodFemaleGenome-Wide Association StudyGenotypeHumansLogistic ModelsMaleMiddle AgedNicotinePolymorphism, Single NucleotidePrecision MedicineSmoking CessationCarbon MonoxideDelayed-Action PreparationsNicotine

Identifiers

PMID20379614
PMCPMC2896464

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.